See more : Global Investments Limited (B73.SI) Income Statement Analysis – Financial Results
Complete financial analysis of Galecto, Inc. (GLTO) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Galecto, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Sydinvest Verden Lav Volatilitet Indeks KL (SYIVLVIKL.CO) Income Statement Analysis – Financial Results
- geechs inc. (7060.T) Income Statement Analysis – Financial Results
- Equitas Small Finance Bank Limited (EQUITASBNK.NS) Income Statement Analysis – Financial Results
- Jiangsu Daybright Intelligent Electric Co.,LTD. (300670.SZ) Income Statement Analysis – Financial Results
- Captiva Verde Wellness Corp. (CPIVF) Income Statement Analysis – Financial Results
Galecto, Inc. (GLTO)
About Galecto, Inc.
Galecto, Inc., a clinical-stage biotechnology company, develops molecules for the treatment of fibrosis, cancer, inflammation, and other related diseases. The company's lead product candidate is GB2064, which is in Phase IIa for the treatment of myelofibrosis. It also develops GB0139, an inhaled inhibitor of galectin-3 that is in Phase IIb clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis, a life-threatening progressive fibrotic disease of the lung; and GB1211, a selective oral galectin-3 inhibitor that is in Phase IIa for the treatment of cancer, as well as in Phase Ib/IIa for fibrosis. Galecto, Inc. was founded in 2011 and is based in Boston, Massachusetts.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 0.00 |
| Gross Profit | -830.00K | -490.00K | -441.00K | -188.00K | -111.00K | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 23.77M | 48.21M | 38.49M | 24.63M | 36.53M | 10.09M |
| General & Administrative | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 12.69M | 13.00M | 13.74M | 9.01M | 2.45M | 2.81M |
| Other Expenses | 3.45M | 0.00 | 0.00 | 0.00 | 1.91M | -479.00K |
| Operating Expenses | 35.63M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Cost & Expenses | 36.46M | 61.21M | 52.23M | 33.64M | 38.97M | 12.91M |
| Interest Income | 1.69M | 722.00K | 156.00K | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 417.00K | 0.00 | 0.00 | 0.00 | 2.97M |
| Depreciation & Amortization | 830.00K | 490.00K | 441.00K | 188.00K | 111.00K | 12.91K |
| EBITDA | -37.52M | -61.13M | -51.31M | -34.65M | -36.40M | -12.90M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -39.91M | -61.21M | -52.23M | -33.64M | -38.97M | -12.91M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.56M | -417.00K | 475.00K | -1.20M | 2.46M | -2.96M |
| Income Before Tax | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 417.00K | -475.00K | 1.20M | 1.91M | 2.48M |
| Net Income | -38.35M | -62.04M | -51.28M | -36.04M | -38.42M | -15.87M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| EPS Diluted | -36.08 | -61.04 | -50.75 | -35.66 | -37.76 | -4.42 |
| Weighted Avg Shares Out | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Weighted Avg Shares Out (Dil) | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
Galecto (GLTO) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now
Galecto (GLTO) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Galecto Reports Third Quarter 2024 Financial Results
- Completed strategic review to focus on oncology and severe liver diseases - Announced acquisition of global rights to BRM-1420, a dual ENL-YEATS and FLT3 inhibitor for multiple genetic subsets of AML from Bridge Medicines - Appointed Dr. Amy Wechsler...
Galecto Strengthens Board of Directors with Appointment of Dr. Amy Wechsler
BOSTON, Oct. 15, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced the appointment of Dr. Amy Wechsler to its Board of Directors. Dr....
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
BOSTON, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that, following an intensive strategic review process, Galecto has determined to focus...
Galecto Announces Reverse Stock Split
BOSTON, Aug. 28, 2024 (GLOBE NEWSWIRE) -- Galecto, Inc. (NASDAQ: GLTO), a clinical-stage biotechnology company focused on the development of novel treatments for cancer and fibrosis, today announced that it will implement a 1-for-25 Reverse Stock Split of its common...
Galecto Announces First Patient Dosed in an Investigator-Initiated Phase 2 Trial of GB1211 in Combination with Pembrolizumab
An NCI-supported Phase 2 investigator-initiated trial at the Providence Cancer Institute in Portland, Oregon, has enrolled its first patient in a study exploring the combination of pembrolizumab (Keytruda®) and Galecto's GB1211, an oral galectin-3 inhibitor, in patients with metastatic melanoma...
Galecto, Inc. (GLTO) Upgraded to Strong Buy: What Does It Mean for the Stock?
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
New Strong Buy Stocks for February 14th
GLTO, LUMN, MORF, SFST and STOK have been added to the Zacks Rank #1 (Strong Buy) List on February 14, 2023.
What Makes Galecto, Inc. (GLTO) a New Strong Buy Stock
Galecto, Inc. (GLTO) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Topline Results from MYLOX-1 Trial Demonstrate Reduction in Fibrosis of the Bone Marrow in Patients with Myelofibrosis
Six of ten evaluable myelofibrosis patients who received GB2064 monotherapy for at least six months experienced a ≥ 1-grade reduction in collagen fibrosis of the bone marrow, validating LOXL2 as a clinical fibrosis target Six of ten evaluable myelofibrosis patients...
Source: https://incomestatements.info
Category: Stock Reports